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Background
In previous studies of PBMC gene expression in s-JIA we
noted a strong erythropoiesis signature in patients with
severe anaemia, correlating with an expansion of CD34+
progenitor cells [1]. Therefore, the origin of anaemia in s-
JIA may be different from anaemia of chronic inflamma-
tion. We examined CD34+ progenitor cells and PBMC
gene expression in patients with s-JIA and other types of
JIA.
Methods
187 patients with JIA (21 s-JIA and 166 other subtypes)
prior to DMARD treatment were studied. PBMCs were iso-
lated using Ficoll gradient centrifugation and analyzed by
flow cytometry after CD34 staining. Gene expression
analysis was performed on Affymetrix HG U133 plus 2.0
arrays.
Results
Patients with s-JIA and anaemia had a significant eleva-
tion of CD34+ cells compared to patients with other JIA
subtypes and anaemia (Table 1). Comparing PBMC gene
expression in patients with s-JIA and anaemia and other
JIA subtypes and anaemia revealed 671 differentially
expressed probes (T-test). Unsupervised hierarchical clus-
tering revealed homogeneous clustering of the s-JIA
group. Strongly divergent gene clusters were identified
with overexpression of erythropoiesis-related genes in
patients with s-JIA.
Conclusion
Patients with s-JIA and anaemia have an increased output
or survival of hematopoietic progenitor cells and a specific
erythropoiesis signature. This contradicts the paradigm
that anaemia in s-JIA is caused by decreased erythrocyte
production due to chronic inflammation. In addition, we
recently showed that many patients with s-JIA have fea-
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Table 1: 
Disease Category N (flow data available) Hb in g/dL CD34+ (% of PBMC)
I. S-JIA (Hb < 11 g/dL) 18 (5) 9.4 ± 1.0* 0.20 ± 0.12*
II. Other JIA (Hb < 11 g/dL) 21 (8) 10.5 ± 0.4* 0.08 ± 0.03*
III. S-JIA (Hb > 11 g/dL) 3 (3) 11.9 ± 1.0* 0.09 ± 0.07*
IV. Other JIA (Hb > 11 g/dL) 145 (82) 12.7 ± 1.0* 0.08 ± 0.05*
P value (ANOVA) 1.65 × 10-6
*Values are represented as mean ± standard deviation. Comparison of CD34+ count via T test: I vs. II: p = 0.008, I vs. III.: p = 0.19, I vs. IV: p = 
0.000001, II vs. III.: p = 0.65, II vs. IV: p = 0.93, III vs. IV: 0.74).Publish with BioMed Central    and   every 
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tures of subclinical macrophage activation syndrome
(MAS) [2]. We hypothesize that anaemia in s-JIA may be
due to hemophagocytosis and subclinical MAS.
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